Antibiotics: FDA Accepts For Review Supplemental New Drug Application for RECARBRIO™

Merck today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for RECARBRIOa (imipenem, cilastatin, and relebactam) to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms. The application has received Priority Review by the FDA, ["]

The post Antibiotics: FDA Accepts For Review Supplemental New Drug Application for RECARBRIOa appeared first on Outbreak News Today.